Trial Profile
Canakinumab in Patients with Chronic Tophaceous Gout, Resistant to Current Treatment Options
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2015
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Gout; Gouty arthritis
- Focus Therapeutic Use
- 27 Jul 2015 New trial record
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.